Interestingly, CD11b+, a myeloid cell marker with potential immunosuppressive properties (“myeloid-deprived suppressor cells”), is decreased after anti-PDL1 antibody treatment when the p38/MAPK pathway is inhibited in glioma-bearing mice with resistance to Temozolomide therapy—a common feature in rGBM patients [61]. The gene discussed is ITGAM; the disease is glioma.